ArticleAbdominal radiology (New York)2026
Quantitative dual-layer spectral CT parameters associated with a continuous improvement response pattern to CAPTEM in advanced gastroenteropancreatic neuroendocrine neoplasms.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo evaluate the prognostic significance of a dynamic continuous improvement (CI) response pattern in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with capecitabine and temozolomide (CAPTEM), and to explore the association between baseline dual-layer spectral CT (DLCT) parameters and this favorable response trajectory.
methodsThis single-center retrospective study (May 2016 - September 2025) analyzed 54 patients treated with CAPTEM. Cox proportional hazards regression models were used to identify prognostic factors affecting progression-free survival (PFS). Patients were stratified via 9-month landmark analysis into CI and non-continuous improvement (NCI) groups. PFS and Time to Nadir (TTN) were compared. Baseline DLCT parameters were analyzed for their association with the CI pattern.
results54 patients (median age, 53 years; 29 men) were evaluated. Peritumoral tissue invasion was independent prognostic factor (p = 0.008; Hazard Ratio [HR], 4.604; 95% confidence interval: 1.495, 14.173). In the landmark cohort, post-landmark PFS was significantly longer in the CI (n = 9) than the NCI (n = 13) group (18.70 vs. 6.47 months; HR, 0.295; 95% confidence interval: 0.100, 0.876; p = 0.044), with a longer TTN (9.67 vs. 6.83 months; p = 0.021). Lower baseline nIC and Zeff values were significantly associated with the CI pattern (median Zeff 8.070 vs. 8.920, p = 0.008; median nIC 0.426 vs. 0.723, p = 0.030).
conclusionThe continuous improvement response pattern was associated with prolonged PFS in GEP-NENs treated with CAPTEM. Baseline DLCT parameters may help identify patients likely to derive sustained benefit from CAPTEM therapy.
Indexed as
Identifiers
42726131What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.